Recombinant human thyroid stimulating hormone in thyroid remnant ablation with 1.1 GBq 131iodine in low-risk patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 2, 2012, Pages 101-104

  Rosario, Pedro Weslley ^a,b   Xavier, Arthur Cezar Malard ^a  

^a Endocrinology Service   (Brazil)

^b Centro de Estudos e Pesquisa da Clinica de Endocrinologia e Metabologia CEPCEM   (Brazil)

Author keywords

Low activity; Recombinant human TS.H.; Thyroid ablation

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROXINE; ANTI THYROGLOBULIN; ANTI-THYROGLOBULIN; AUTOANTIBODY; RADIOACTIVE IODINE;

ADULT; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SIZE; CANCER SURGERY; FEMALE; HUMAN; HYPOTHYROIDISM; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; THYROID CANCER; THYROIDECTOMY; TUMOR ABLATION; AGED; BLOOD; DRUG ADMINISTRATION; ECHOGRAPHY; FOLLOW UP; MIDDLE AGED; NEEDLE BIOPSY; RISK FACTOR; THYROID TUMOR; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AUTOANTIBODIES; BIOPSY, FINE-NEEDLE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOTHYROIDISM; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN ALFA; THYROXINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84860443135     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318201a41a     Document Type: Article

References (33)

1. Cooper DS, Doherty GM, Haugen BR, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19:1167-1214.
2. Haugen BR, Cooper DS, Emerson CH, et al. Expanding indications for recombinant human TSH in thyroid cancer. Thyroid. 2008;18:687-694. (Pubitemid 352009942)
3. Pitoia F, Ward L, Wohllk N, et al. Recommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2009;53:884-887.
4. Biondi B, Pulcrano M, Pagano L, et al. Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer. Biologics. 2009;3:9-13.
5. Molinaro E, Viola D, Passannanti P, et al. Recombinant human TSH (rhTSH) in 2009: New perspectives in diagnosis and therapy. Q J Nucl Med Mol Imaging. 2009;53:490-502.
6. European Medicines Agency. Doc. Ref: EMEA/CHMP/745393/ 2009.
7. Food and Drug Administration. Thyrogen (NDA 020898) label approved on 08/12/2008.
8. Hay ID, Thompson GB, Grant CS. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): Temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879-885. (Pubitemid 36920280)
9. Rosario PW, Borges MA, Valadão MM, et al. Is adjuvant therapy useful in patients with papillary carcinoma smaller than 2 cm? Thyroid. 2007;17:1225-1228.
10. Rosario PW, Fagundes TA, Rezende LL, et al. Assessing hypothyroidism in the preparation of patients with thyroid cancer: Cardiovascular risk, renal function, drug metabolism, persistence of elevated thyroid-stimulating hormone, and absence from work. Endocrinologist. 2006;16:25-29. (Pubitemid 44378688)
11. Rosario PW, Borges MA, Purisch S. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity. J Nucl Med. 2008;49:1776-1782.
12. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89: 1638-1644. (Pubitemid 37464133)
13. Rosario PW, Barroso AL, Rezende LL, et al. Testicular function alter radioiodine therapy in patients with thyroid cancer. Thyroid. 2006;16:667-670.
14. Souza-Rosario PW, Alvarenga-Fagundes T, Villasboas Fagundes AS, et al. Ovarian function after radioiodine therapy in patients with thyroid cancer. Exp Clin Endocrinol Diabetes. 2005;113: 331-333.
15. Rosario PW, Maia FF, Barroso A, et al. Sialoadenitis following ablative therapy with high doses of radioiodine for treatment of differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2004;48:310-314.
16. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803. (Pubitemid 43997716)
17. Rosario PW, Fagundes TA, Purisch S, et al. Recombinant TSH in ablative therapy and follow-up of patients with differentiated thyroid carcinoma. Arq Bras Endocrinol Metabol. 2005;49: 350-358.
18. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: Effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab. 2003;88:4110-4115. (Pubitemid 37153707)
19. Pacini F, Ladenson P, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: Results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926-932. (Pubitemid 43357760)
20. Zulewski H, Müller B, Exer P, et al. Estimation of tissue hypothyroidism by a new clinical score: Evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab. 1997;82:771-776. (Pubitemid 27106585)
21. Rosario PW, Faria S, Bicalho L, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med. 2005;24:1385-1389. (Pubitemid 41395927)
22. Rosario PW, Tavares Júnior WC, Biscolla RP, et al. Usefulness of neck ultrasonography in the follow-up of patients with differentiated thyroid cancer. Arq Bras Endocrinol Metabol. 2007;51: 593-600.
23. Frigo A, Dardano A, Danese E, et al. Chromosome translocation frequency after radioiodine thyroid remnant ablation: A comparison between rhTSH stimulation and prolonged levothyroxine withdrawal. J Clin Endocrinol Metab. 2009;94:3472-3476.
24. Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroidstimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun. 2006;27: 627-632. (Pubitemid 44305303)
25. Barbaro D, Grosso M, Boni G, et al. Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: The effect of pre-treatment with furosemide and furosemide plus lithium. Eur J Nucl Med Mol Imaging. 2010;37:242-249.
26. Lee J, Yun MJ, Nam KH, et al. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid. 2010;20:173-179.
27. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131I: A comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002;87:4063-4068.
28. Emmanouilidis N, Müller JA, Jäger MD, et al. Surgery and radioablation therapy combined: Introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH. Eur J Endocrinol. 2009;161: 763-769.
29. Tala Jury HP, Castagna MG, Fioravanti C, et al. Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab. 2010;95:230-237.
30. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700MBq (100 mCi) 131I administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92:3542-3546. (Pubitemid 47435333)
31. Baudin E, Do Cao C, Cailleux AF, et al. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003;88:1107-1111. (Pubitemid 36337763)
32. Valadão MM, Rosário PW, Borges MA, et al. Positive predictive value of detectable stimulated Tg during the first year after therapy of thyroid cancer and the value of comparison with Tgablation and Tg measured after 24 months. Thyroid. 2006;16: 1145-1149. (Pubitemid 44864489)
33. Schlumberger M, Pacini F. Distant Metastases. In: Schlumberger, Pacini, eds. Thyroid Tumors. 3rd ed. Paris: Éditions Nucléon; 2006.